NicodermCQ — Competitive Intelligence Brief

NicodermCQ (NicodermCQ) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nicotine replacement therapy (NRT). Area: Smoking Cessation / Addiction Medicine.

marketed Nicotine replacement therapy (NRT) Nicotinic acetylcholine receptors Smoking Cessation / Addiction Medicine Small molecule

Target snapshot

NicodermCQ (NicodermCQ) — University of Chicago. NicodermCQ delivers nicotine transdermally to replace nicotine from cigarettes and reduce withdrawal symptoms during smoking cessation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
NicodermCQ TARGET	NicodermCQ	University of Chicago	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
patch + lozenge	patch + lozenge	University of Wisconsin, Madison	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
Fentanyl/Atropine/Succinylcholine	Fentanyl/Atropine/Succinylcholine	King Saud University	marketed	Anesthetic combination (opioid + anticholinergic + neuromuscular blocker)	Mu-opioid receptor (fentanyl); muscarinic acetylcholine receptors (atropine); nicotinic acetylcholine receptors at neuromuscular junction (succinylcholine)
Transdermal Nicoderm patch	Transdermal Nicoderm patch	Ottawa Heart Institute Research Corporation	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors
Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge	Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge	University of Wisconsin, Madison	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
Chantix	Varenicline Tartrate	Pfizer Inc.	marketed	Nicotinic receptor partial agonist	α4β2 neuronal nicotinic acetylcholine receptors
nicotine patch plus nicotine gum/lozenge	nicotine patch plus nicotine gum/lozenge	University of Minnesota	marketed	Nicotine replacement therapy (NRT) combination	Nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2035-10-19 — Chantix · 11224598 · Method of Use · US
• 2035-10-19 — Chantix · 10456396 · Formulation · US
• 2035-10-19 — Chantix · 9597284 · Method of Use · US
• 2035-10-19 — Chantix · 9532944 · Method of Use · US
• 2035-10-19 — Chantix · 9504644 · Method of Use · US
• 2035-10-19 — Chantix · 11911380 · Method of Use · US
• 2035-10-19 — Chantix · 11903943 · Method of Use · US
• 2035-10-19 — Chantix · 11903941 · Method of Use · US
• 2035-10-19 — Chantix · 9504645 · Formulation · US
• 2035-10-19 — Chantix · 11903942 · Formulation · US

Sponsor landscape (Nicotine replacement therapy (NRT) class)

1. University of Wisconsin, Madison · 4 drugs in this class
2. Ottawa Heart Institute Research Corporation · 1 drug in this class
3. The Scripps Research Institute · 1 drug in this class
4. US Department of Veterans Affairs · 1 drug in this class
5. Chrono Therapeutics, Inc. · 1 drug in this class
6. University of Chicago · 1 drug in this class
7. University of Maryland, Baltimore · 1 drug in this class
8. University of Miami · 1 drug in this class
9. University of California, San Francisco · 1 drug in this class